$BHC fawk that spinoff. Approach Takeda for the 10B that was on the table. Xifaxan has now more revenue and a long patent defended. Shed most of that ridiculous annual 1.6B interest cost. And then you can compare it with Alcon and Cooper.
  • 7
7 Likes